文献速递MDS 与骨髓增殖性肿瘤血栓与止血

原发性血小板增多症:新药在即的当代诊疗策略

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.
PubMed 文献 · Br J Haematol · 2024-04-08

本综述聚焦原发性血小板增多症(ET)治疗策略的演变,强调分子分型在指导治疗决策中的作用。修订版IPSET-血栓形成评分已纳入多数专家推荐,抗血小板药和常规降细胞药物仍是治疗基石,新型疗法可能改善结局。

要点

  • ET患者传统上按年龄>60岁和血栓史分为两个血栓风险类别。
  • 修订版IPSET-血栓形成评分考虑了JAK2突变相关风险,已纳入多数专家推荐。
  • 抗血小板药和常规降细胞药物仍是治疗基石,新药可能改善结局。

核心结论

  • 本综述关注ET治疗策略的演变,强调分子分型在指导治疗决策中的作用,并针对CALR突变、MPL突变和三阴性ET及高风险突变患者提供具体观察。

研究设计与样本

  • 本文为综合性综述,检索范围原文未报告。

主要发现

  • ET是一种骨髓增殖性肿瘤,以血管并发症风险增加和向骨髓纤维化及急性白血病进展倾向为特征。
  • ET患者传统上根据年龄>60岁和血栓史分为两个血栓风险类别。
  • 修订版IPSET-血栓形成评分考虑了JAK2突变相关风险增加,已纳入多数专家推荐。
  • 越来越多证据表明ET包含不同基因组实体,各自具有不同临床病程和预后。
  • 降细胞和抗血小板治疗的有效性和毒性因分子基因型而异。

关键数值与推荐

  • 抗血小板药和常规降细胞药物(主要为羟基脲、阿那格雷和聚乙二醇干扰素)仍是治疗基石。
  • 近期研究揭示了新型疗法的有效性,可能有助于改善结局。
  • 修订版IPSET-血栓形成评分已纳入多数专家推荐。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essential thrombocythaemia (ET) is a myeloproliferative neoplasm characterized by an increased risk of vascular complications and a tendency to progress to myelofibrosis and acute leukaemia. ET patients have traditionally been stratified into two thrombosis risk categories based on age older than 60 years and a history of thrombosis. More recently, the revised IPSET-thrombosis scoring system, which accounts for the increased risk linked to the JAK2 mutation, has been incorporated into most expert recommendations. However, there is increasing evidence that the term ET encompasses different genomic entities, each with a distinct clinical course and prognosis. Moreover, the effectiveness and toxicity of cytoreductive and anti-platelet treatments differ depending on the molecular genotype. While anti-platelets and conventional cytoreductive agents, mainly hydroxycarbamide (hydroxyurea), anagrelide and pegylated interferon, remain the cornerstone of treatment, recent research has shed light on the effectiveness of novel therapies that may help improve outcomes. This comprehensive review focuses on the evolving landscape of treatment strategies in ET, with an emphasis on the role of molecular profiling in guiding therapeutic decisions. Besides evidence-based management according to revised IPSET-thrombosis stratification, we also provide specific observations for those patients with CALR-, MPL-mutated and triple-negative ET, as well as cases with high-risk mutations.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ferrer-Marín F, Hernández-Boluda JC, Alvarez-Larrán A, et al. Essential thrombocythaemia: A contemporary approach with new drugs on the horizon. Br J Haematol. 2024. PMID: 38586911. doi:10.1111/bjh.19403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。